Senior VP of Operations at Seneca Therapeutics, Hung Trinh, has shared an update on the current progress and future perspectives of RNA-based cancer vaccines. These breakthrough treatments train the immune system to recognize and attack specific cancer cells.
Recent clinical trials have shown impressive results, with one melanoma treatment reducing cancer recurrence by 44% when combined with existing immunotherapy. The field has gained significant momentum in 2024-2025, with major advances in pancreatic and brain cancer treatments, supported by over 120 ongoing clinical trials.
Artificial intelligence is helping scientists identify the best cancer targets, while manufacturing improvements have reduced production time from nine weeks to under four weeks. Over 60 treatments are currently in development, with first commercial approvals expected by 2029.
RNA-based cancer vaccines represent a significant advancement in personalized cancer care, offering new hope for patients with various types of cancer.
Source: https://oncodaily.com/insight/hung-trinh-350972